Results 121 to 130 of about 19,263 (243)

Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance. [PDF]

, 2016
Aarts-Riemens, T, de Bruijn, J, de Haart, SJ, Doshi, P, Emmelot, ME, Groen, RWJ, Holthof, L, Lokhorst, HM, Martens, ACM, Minnema, MC, Mutis, T, Noort, WA, Sasser, K, van de Donk, NWCJ, Yuan, H   +14 more
core   +3 more sources

Daratumumab monotherapy for relapsed POEMS syndrome [PDF]

, 2023
Danai Dima, Jason Valent, Jack Khouri
openalex   +1 more source

Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review [PDF]

This systematic review examines the available clinical data on CD34+ cell mobilization, collection, and engraftment in multiple myeloma patients treated with the anti-CD38 monoclonal antibodies daratumumab and isatuximab in clinical trials and in real ...
Barbato S., Bigi F., Cavo M., Iezza M., Mancuso K., Manzato E., Masci S., Pantani L., Puppi M., Restuccia R., Rizzello I., Sacchetti I., Sartor C., Tacchetti P., Talarico M., Zamagni E.   +15 more
core   +1 more source

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review

Frontiers in Oncology
BackgroundSince no randomized controlled trials have directly compared the efficacy and safety of immunotherapy with daratumumab versus lenalidomide/bortezomib/dexamethasone (RVD) in the frontline treatment of transplant-ineligible newly diagnosed ...
Wenjiao Tang, Li Zhang, Yuhuan Zheng, Ling Pan, Ting Niu   +4 more
doaj   +1 more source

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study [PDF]

Ajai Chari, Niels W.C.J. van de Donk, Bhagirathbhai Dholaria, Katja Weisel, María‐Victoria Mateos, Hartmut Goldschmidt, Thomas G. Martin, Daniel Morillo, Donna Reece, Paula Rodríguez‐Otero, Manisha Bhutani, Anita D’Souza, Albert Oriol, Laura Rosiñol, Nizar J. Bahlis, Deeksha Vishwamitra, Sheri Skerget, Raluca Verona, Kalpana Bakshi, Lijuan Kang, Thomas J. Prior, Lien Vandenberk, Jaszianne Tolbert, Sangmin Lee, Damiette Smit, Ralph Wäsch   +25 more
openalex   +1 more source

Daratumumab for Treatment of Acute Antibody‐Mediated Rejection in a Pediatric Kidney Transplant Recipient [PDF]

H. Connolly, Ally Watson, Michael Wynd, Kenneth V. Lieberman, Melissa Chaung, Michael J. Goldstein, Guillermo Hidalgo, Ibrahim Batal, Marlene R. Amoruso, Namrata G. Jain   +9 more
openalex   +1 more source

P183 | DELAYED DARATUMUMAB ADDITION TO LENALIDOMIDE-DEXAMETHASONE IN OLDER MULTIPLE MYELOMA PATIENTS: INSIGHTS FROM REAL-WORLD DATA

Haematologica
Introduction In patients (pts) with multiple myeloma (MM), the combination of daratumumab, lenalidomide, and dexamethasone (Dara-Rd) is a standard of care, approved both for frontline treatment of non-transplant eligible (NTE) pts and in the relapsed ...
L. Cani, A. Di Nicola, A. Evangelista, I. Delle Donne, G. Bertuglia, A. Casson, M. D’agostino, F. Gay, A. Larocca, E. Marchetti, R. Mina, S. Oliva, T. Picardi, B. Bruno, S. Bringhen, G. Benevolo   +15 more
doaj  

MagnetisMM-6 part 2: A phase 3, open-label, randomized study of elranatamab in combination with daratumumab and lenalidomide vs daratumumab, lenalidomide, and dexamethasone in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma [PDF]

Ja Min Byun, Meletios Α. Dimopoulos, Eeman Shaikh, Karen Gogat-Marchant, N Green, Domenico Cieri, Hang Quach   +6 more
openalex   +1 more source

Effective front-line treatment of osteosclerotic myeloma with POEMS syndrome with daratumumab, lenalidomide and dexamethasone: a case report and literature review [PDF]

Chiel Gharakhani, A Soetens, Wouter Huysse, Philippe Decruyenaere, Nicolas Kint   +4 more
openalex   +1 more source

Ex-Vivo Testing of Myeloma Cells and Autologous Effector Cells from the Tumor Microenvironment Unveils Differential Response to Daratumumab and Isatuximab [PDF]

Constanza Marín, Maribel Nicola, Diego Andino, Maria Laura Bernaschini, Gimena Ferreira, Alejandro Moyano, Magali E. Ridano, Reinaldo Campestri, Francisco Bernal Julián, Gustavo Jarchum, Sol Jarchum, Pablo Andrés García, Juan José Roig García, Miguel Barrueco Ferrero, Veronica Seifi, Guillermina Remaggi, Tarek Ali Zaki, Candelaria Llorens, Gerardo Gatti, Daniela Arroyo, Gastón Soria   +20 more
openalex   +1 more source